Halle Moore, MD
Hematology & Oncology · Cleveland, OHNPI 1700840683
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Myovant Sciences Inc. at 57.4% of the total. That places this record below the midpoint for hematology & oncology clinicians in OH, where the typical reported total is $2,354.
Across 7 payments — averaging $337.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myovant Sciences Inc.$1K
- AstraZeneca$910
- Servier Pharmaceuticals LLC$84
- Gilead$12
Across 119 payments — averaging $14,697 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.2M
- Seagen Inc.$177K
- Daiichi Sankyo Inc.$157K
- AstraZeneca$145K
- Merck$36K
- Astrazeneca UK Limited$33K
- plus $40K from 3 others
What the payments were for
- Consulting fees$1,35657%
- Speaking & faculty fees$67429%
- Travel & lodging$22810%
- Food & beverage$924%
- Education$121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myovant Sciences Inc. | 1 | $1,356 |
| AstraZeneca | 4 | $910 |
| Servier Pharmaceuticals LLC | 1 | $84 |
| Gilead | 1 | $12 |
How this compares
$2,362 in reported general payments places this provider in the 50th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 67 | $926,309 |
| IbrancePalbociclib | 11 | $170,321 |
| VerzenioAbemaciclib | 11 | $169,720 |
| Exemestane | 40 | $8,383 |
| Anastrozole | 162 | $3,150 |
| Letrozole | 96 | $2,161 |
| Tamoxifen Citrate | 26 | $820 |
| Ondansetron Hcl | 35 | $312 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $217 |
| Prochlorperazine Maleate | 16 | $159 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Cleveland
- Hillard LazarusCleveland$2M
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Bachar DerghamCleveland$387K
- Brian HillCleveland$316K
- Dale ShepardCleveland$314K
- Sakti ChakrabartiCleveland$301K
- Keith McCraeCleveland$215K
- Megan KruseCleveland$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.